Company intelligence / Profile preview
Elpis Biopharmaceuticals
Lexington, Massachusetts, USAelpisbiopharmaceuticals.com ↗
- Ownership
- Private
- Employees
- ~12
- Development stage
- Other
01
Overview
The company has advanced from pre-clinical to clinical stage with lead programs including EPC-003 for glioblastoma and EPC-002 for solid tumors. Recent data presented at AACR 2025 showed EPC-003 induced tumor regression in GBM mouse models as early as day 6 following intracranial injection and successfully penetrated the blood-brain barrier with IV administration.
- Therapeutic areas
- Oncology
- Modalities
- CAR-T cell therapiesbispecific antibodiesimmunomodulatorsengineered cytokines
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Beyond the preview
Go deeper on Elpis Biopharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Elpis Biopharmaceuticals.